In November 1999, the National Drugs and Poisons Schedule Committee (NDPSC) decided to reschedule mometasone from Schedule 4 to Schedule 3 for use in aqueous nasal sprays for the treatment of seasonal allergic rhinitis, with certain dose and age conditions. The NDPSC considered that this rescheduling was appropriate given mometasone's safety in use based on pharmacokinetic parameters, and that the treatment of seasonal allergic rhinitis has a place in Schedule 3.
Just as the name suggests, GHRH helps to stimulate secretion of growth hormone. The duration of secretion induced will depend on the specific type of peptide that you use. An important thing to note here is that these substances are effective only to a limit. Exceeding the saturation dose, which may vary between individuals, will not improve the amount of HGH that is secreted. Below are a few peptides that fall in the GHRH group.
In studies GHRP-6 has shown biological actions similar to the naturally occurring hunger stimulating peptide ghrelin. Its main use is to promote food intake by stimulating hunger and aid in energy metabolism. It can be used in the treatment of GH deficiency as well as cachexia, eating disorders and obesity. GHRP-6 is a synthetic met-enkephalin (a naturally occurring opioid growth factor) analog. GHRP-6 contains D-amino acids that are entirely synthetic, lacks opioid activity, and shares no sequence relation with GHRH. It has also been shown that GHRP-6 can lead to re-stimulation of the natural production of HGH.
The letters stand for ‘Growth Hormone Releasing Peptide’, and the compound is a peptide in the growth factor family, known as a HEXAPEPTIDE and GH SECRATAGOGUE. It has a strong effect on the release of endogenous (naturally produced) human growth hormone, in a dose related manner. It has been used in school medicine for the treatment of growth hormone deficiency in children and young adults, which drives home just how powerful this compound is at influencing the body to release its own natural GH. It works by signalling the pituitary gland to secrete GH itself, but also by the suppression of SOMATOSTATIN too (an antagonist of growth hormone releasing hormone – GHRH).
One of the other uses for GHRP-6 is to kick start your own GH after a cycle, a dose of 200-500mcg 2x a day is sufficient to start your own GH; however, it does not mean your own GH levels will be where they were before you carried out your cycle, this is user dependent. It will certainly be a very useful addition to any hormonal cycles' PCT, as the increased IGF-1 levels it brings will greatly increase the chances of you holding on to any muscle you have gained.
Furthermore, the most potent profibrogenic growth factors: Tgfb1, Pdgfb, and Ctgf also appeared significantly underexpressed in the GHRP-6-treated wounds (all ) (Figure 4). In line with this, we observed a significant reduction in the expression levels of Col1a1 and Col3a1 (Figure 4, both ). Concomitantly, we addressed the attention to filamentous and contractile proteins associated with fibroblasts and other differentiated mesenchyme-derived cells. Acta2 appeared close to a significant reduction (), whereas Des, Vim, and Fn transcriptional expression appeared significantly reduced (all ), as compared to placebo-treated wounds.
Bremelanotide PT 141 was developed from Melanotan II, targeting its aphrodisiac effects. This peptide has been shown to have a substantial effect on libido, generating sexual arousal in both men and women within minutes of administration. It has been shown to be effective in treating erectile dysfunction, even in men who have not responded to other ED treatments, such as Viagara. This peptide is also able to cross the blood-brain-barrier, bypassing the vascular system and acting at the level of the central nervous system. This property gives Bremelanotide an advantage over traditional ED drugs, which can decrease blood pressure to dangerous levels. This peptide can be administered as a nasal spray, making its use convenient and discreet.
A peptide is an amino acid chain (amino acids being the building blocks of proteins), responsible for signalling different responses in the body. These amino chains already exist in the body in one form or another, which is why some consider them as ‘natural’ compounds (although testosterone exists in the human body too, adding extra is considered cheating in most cases). Peptides have been classified in research and manufacture according to a number sequence in many cases, which is why some are just numbers and letters (see later).
The original GRF (1-29) has a half-life of about 30 minutes. Half-life means the time within which half of the hormone administered will be destroyed within the body. This short half-life is due to the fact that the compound is highly unstable and breaks down soon. To increase its stability and to make it last longer, it was modified by adding 4 amino acids in its structure. This gave it the name Modified GRF (1-29) or Mod GRF 1-29. It was originally invented by DatBtrue. The portion of the molecule that actually stimulates the growth hormone secretion is found in the chain of 29 amino acids, so it is named GRF (1-29). This chemical also produces slow-wave sleep.

If GHRP-6 is powerful for growth hormone release, this peptide is even stronger, albeit slightly so. GHRP-2 is used for similar purposes as the other compound. But it does not fire up appetite as the other peptide is known to do. This may make it more ideal for people interested in improving lean muscle mass. Furthermore, it does not desensitize when taken in low doses without observing breaks as required for other peptides.


The medicines delegate referred the proposal to upschedule paracetamol/ibuprofen from Schedule 2 to Schedule 3 to the Advisory Committee on Medicines Scheduling (ACMS) in early 2011. The proposal was submitted by the Advisory Committee on Non-Prescription Medicines (ACNM) as they were currently assessing a product in which the sponsor did not satisfactorily establish the efficacy and safety of the product and that public health concerns raised during the assessment of the product could be addressed by access to a pharmacist. AFT Pharmaceuticals had submitted a product application with the TGA at the time of this item being considered by the delegate and ACMS.
According to pilot studies, our group determined that 400 μg/mL represented an optimal dose level by reducing inflammation, promoting collagen fibers alignment, while aborting the onset of HTS in rabbit ears. A lower dose (200 μg/mL) did not prevent the exuberant phenotype whereas a higher dose (800 μg/mL) delayed reepithelialization in rats and rabbits (data not shown).
also using a dose of 400mcg for the IPAM is really a waste of your peptides as anything above saturation dose will give diminished returns, saturation dose(1mcg per kg) is a dose that will give maximum return, if you double the saturation dose then you will not get double the GH pulse in fact no where near that, then the more you use the less added benefit you will get.
"I Ordered PH400 , both my training partner and I have trained for a few years now and thought lets try something new. We only did one bottle each. We increased our eating (clean) and within a week we were already training twice a day 4 times a week after a month i had put on approx 5kg (1-1.5kg muscle) . I recovered almost overnight and my ability to up weight between sets was definately a motivator and it wasnt just a pump after workouts it would actually stay. Even after being off it i had to ease off the training a my body couldn't push as much and recover in time , but we willl definatley begetting back on it again this time for a full 3 months and do a full stack. Would definately recommend PH and there is no taste i added it to my morning shake just one vile a day for 30 days , wouldnt need anymore than that. Also there were no side effects , but to see best results you want to train more often and increase food intake." Daniel Ram

GHRPs bind to two different receptors (GHS-R1a and CD36), which redundantly or independently exert relevant biological effects. GHRPs’ binding to CD36 activates prosurvival pathways such as PI-3K/AKT1, thus reducing cellular death. Furthermore, GHRPs decrease reactive oxygen species (ROS) spillover, enhance the antioxidant defenses, and reduce inflammation. These cytoprotective abilities have been revealed in cardiac, neuronal, gastrointestinal, and hepatic cells, representing a comprehensive spectrum of protection of parenchymal organs. Antifibrotic effects have been attributed to some of the GHRPs by counteracting fibrogenic cytokines. In addition, GHRP family members have shown a potent myotropic effect by promoting anabolia and inhibiting catabolia. Finally, GHRPs exhibit a broad safety profile in preclinical and clinical settings. Despite these fragmented lines incite to envision multiple pharmacological uses for GHRPs, especially as a myocardial reperfusion damage-attenuating candidate, this family of “drugable” peptides awaits for a definitive clinical niche.

One common concern when it comes to GHRP-6 doses (or the doses of any Ghrelin mimetic/GHRP) is the fact that it has been found to exhibit the ability to induce secretion of Cortisol and Prolactin. While many studies have indeed demonstrated this[5], they have also demonstrated that the Prolactin and Cortisol increases in most test subjects were not altered at all at GHRP-6 doses of 100mcg or less[6] [7]. GHRP-6 doses that are increased above 100mcg will exhibit increased Cortisol and Prolactin secretion, but minimally. As the dose is further increased, it stands to reason that the Cortisol and Prolactin secretions will increase as well.

GHRPs bind to two different receptors (GHS-R1a and CD36), which redundantly or independently exert relevant biological effects. GHRPs’ binding to CD36 activates prosurvival pathways such as PI-3K/AKT1, thus reducing cellular death. Furthermore, GHRPs decrease reactive oxygen species (ROS) spillover, enhance the antioxidant defenses, and reduce inflammation. These cytoprotective abilities have been revealed in cardiac, neuronal, gastrointestinal, and hepatic cells, representing a comprehensive spectrum of protection of parenchymal organs. Antifibrotic effects have been attributed to some of the GHRPs by counteracting fibrogenic cytokines. In addition, GHRP family members have shown a potent myotropic effect by promoting anabolia and inhibiting catabolia. Finally, GHRPs exhibit a broad safety profile in preclinical and clinical settings. Despite these fragmented lines incite to envision multiple pharmacological uses for GHRPs, especially as a myocardial reperfusion damage-attenuating candidate, this family of “drugable” peptides awaits for a definitive clinical niche.
Although the history of some of the foremost biomedical discoveries is permeated by serendipity,4 we deem that the well-established pivotal role of the GH/insulin-like growth factor-1 (IGF-1) axis for cardiomyocyte physiology, and the subtle alterations of this axis within the pathogenicity of dilated cardiomyopathy (DCM) and left ventricular (LV) dysfunction, ignited the idea of assessing the potentiality of GHRP to alleviate cardiac pathologies.5 It was far to be anticipated on those early days, however, that the GHRP-mediated cardiotropic and cytoprotective effects are superior to those shown by the exogenous administration of GH and are not shared by GH-releasing hormone (GHRH) and that, importantly, GHRPs exert their pharmacological actions via GH-independent pathways that obviously represented another turning point in this history.3

Extreme hunger stimulation: It has been previously mentioned in this profile already that almost all GHRPs will stimulate hunger simply by virtue of the fact that they are Ghrelin mimetics (they mimic the action of the hormone Ghrelin in the body), but GHRP-6 has demonstrated both anecdotally as well as clinically to stimulate the largest hunger increases in comparison to all other GHRPs[2]. GHRP-6 tends to stimulate what can only be described as agonizing hunger, and is commonly misconceived as a hypoglycemic episode. The hunger resultant from GHRP-6 is, in fact, simply the peptide acting on Ghrelin receptors that signal hunger to various regions in the brain. No studies or any anecdotal evidence demonstrates hypoglycemic blood glucose readouts following GHRP-6 administration. Following a meal, the hunger should subside. Many users have also reported the intensity of the hunger diminishing several weeks into GHRP-6 cycles but not completely disappearing.
Sufficient data was not available on the therapeutic use of non-steroidal SARMs. No SARMs were currently marketed, however enobosarm was undergoing clinical trials in a range of medical conditions such as cachexia, sarcopenia, osteoporosis and frailty. These conditions require medical diagnosis, monitoring and management, i.e. scheduling factors for Schedule 4.
For example, there are Growth Hormone Releasing Peptides (GHRP’s with names such as ipamorelin and hexarein) which allow for a slow and steady growth hormone release that produces a pulse which mimics natural growth hormone release times and Growth Hormone Releasing Hormones (GHRH’s such as Mod-GRF) for an even stronger natural release of growth hormone and greater presence of growth hormone precursors known as GH “frags” or fragments.
In August 2010, the delegate confirmed the decisions of the June 2010 meeting of the NDPSC to transfer leflunomide to Appendix L. Appendix L was a new appendix created to list all of the requirements for dispensing labels previously included in the body of the Poisons Standard (i.e. paragraph 45, Dispensed Medicines, of Part 3, Miscellaneous Regulations) as part of the transitional amendments required to change the Standard for the Uniform Scheduling of Drugs and Poisons No. 24 into the Standard for the Uniform Scheduling of Medicines and Poisons No. 1, under the revised scheduling arrangements commencing 1 July 2010.
The two peptides CJC 1295 Ipamorelin, are often used in conjunction for better results. Known individually as CJC 1295 and Ipamorelin, these peptides have similar roles, which we will look at later. But for now, the CJC 1295 and Ipamorelin combination, is chiefly used together because the production of growth hormone secretion is 10 times more effective than using them individually. This makes it convenient for most users, to guarantee quicker results. Above all, it is popular among athletes, bodybuilders and weightlifters in need of building strength or speeding up the recovery of an injury.
Another benefit of CJC 1295 is its ability to promote slow wave sleep. Slow wave sleep is also known as deep sleep and is the portion of sleep responsible for the highest level of muscle growth and memory retention. SWS decreases significantly in older adults and also with people who tend to exercise later in the evening. Clinical studies have shown that a once-daily administration of CJC 1295 normalizes the GHRH response and can induce significantly deeper sleep.

Conclusions: Subcutaneous administration of CJC 1295 resulted in sustained, dose-dependent increases in GH and IGF-I levels in healthy adults and was safe and relatively well tolerated, particularly at doses of 30 or 60 ug/ kg. There was evidence of a cumulative effect after multiple doses. These data support the potential utility of CJC 1295 as a therapeutic agent.
Since CD36 is implicated in angiogenesis regulation, special attention was addressed to the population of neovessels as to their general morphology. By routine staining, we ascertained that GHRP-6 treatment did not reduce the number of vessels, which also exhibited normal structure, organization, and distribution. Furthermore, CD31 expression was detected in all these vascular structures suggesting mature angiogenesis. Conclusively, GHRP-6 administration did not hinder wound angiogenesis in any respect (Figure 3(a)), as compared to placebo-treated wounds (Figure 3(b)). These histological findings support the scoring on the ECM maturation and the quantification of inflammatory cells across the wounds (Table 2).
"In circumstances where a medicine is widely known to be used in connection with modifying a physiological process in persons (as appears to be the case with some SARMs and other peptide products), that medicine is likely to satisfy the definition of a therapeutic good despite any disclaimer to the effect that it is for research purposes only and/or not for human use."
The qualitative microscopic analysis of the GHRP-6 responsive wounds indicated that the peptide seems to primarily reduce both local hypercellularity associated with the cartilage perichondrium cells and the resulting ECM accumulation (Figures 6(a) and 6(b)). Accordingly, their SEI () appeared largely different () as compared to the placebo samples group (). It is notorious, however, that those GHRP-6 nonresponsive wounds () that evolved to HTS exhibited similar microscopic appearance (not shown) and SEI values as compared to placebo control wounds (Table 3).
GHRP-6 stands for growth hormone releasing hexapeptide, so it is obviously a peptide hormone. As you can probably guess, it acts in the same manner as all peptides do in the Growth Hormone (GH) class – it increases the amount of GH our bodies produce. This is a very beneficial property, as growth hormone is the fountain of youth, and serves many purposes from fat loss, to muscle gain and anti-aging effects. For this reason many athletes have turned to GHRP-6 in order to get an athletic edge.
Total RNA was purified according to TRI Reagent standard procedure (Sigma, USA), following digestion with RQ1 DNase I (Promega, USA) to remove contaminating genomic DNA. Afterward, 500 ng of DNA-free RNA was reverse transcribed using Omniscript RT kit (Qiagen, Germany) with oligo-dT primer. The RT reaction was performed at 42°C for 60 min. PCR mixtures contained 1 μL cDNA, 1 μL of each primer (10 μM), and 12.5 μL 2x Taq MasterMix (Qiagen, Germany) in a final volume of 25 μL. Specific sense and antisense primers, annealing temperatures, and number of repeating cycles for both studies are referred to in Table 1. Amplifying conditions were performed as follows: a first step of 95°C for 5 minutes, thereafter repeating cycles comprised of 95°C for 30 seconds, specific annealing temperature for 30 seconds and 72°C for 30 seconds, and a final extension step of 5 minutes at 72°C. PCR bands (8 μL of PCR product plus 2 μL of gel loading buffer) were resolved on 1.5% (w/v) agarose gel electrophoresis and visualized under ultraviolet light subsequent to being stained with ethidium bromide. PCR products were quantified using the Kodak ID 3.6 software package (Kodak Inc, USA). Beta-2 microglobulin was used as housekeeping gene for normalization.
SARMs stimulate androgen receptors specifically in muscle and bone cells, hence assisting with muscle and bone growth, while having little effect on the other cells in the body (unlike regular steroids). They have a special affinity for certain tissues like muscle and bone, but not for others, like the prostate, liver, and brain. This means more rapid muscle and bone growth without unwanted growth in other parts of your body.
One of the other uses for GHRP-6 is to kick start your own GH after a cycle, a dose of 200-500mcg 2x a day is sufficient to start your own GH; however, it does not mean your own GH levels will be where they were before you carried out your cycle, this is user dependent. It will certainly be a very useful addition to any hormonal cycles' PCT, as the increased IGF-1 levels it brings will greatly increase the chances of you holding on to any muscle you have gained.

Researchers around the globe suggest that the effectiveness of growth hormones depends a lot on the physical condition of the subject being administered with the drug. If the subject is obese, then there may not be the desired level of hormone secretion. Obesity seems to affect the effectiveness of GHRP-6 but if the subjects are not obese, the effects of this drug is likely to be the same for all gender or age groups, subject to the administered dosage.
In a study designed to assess the effect of both the estrogen and GHRP-6 on the cardiovascular and metabolic diseases in ovariectomized (OVX) rats, Elbassuoni, et al found that although GHRP-6 failed to produce significant change in body weight gain and food intake, it clearly reversed the effect of OVX on fasting serum glucose, insulin, insulin resistance, and the assessed lipid fractions. They concluded that the effect of GHRP-6 on improving dyslipidemia after OVX was even more potent than that of estrogen.12 Furthermore, the mechanism of action of GHRP-6 has been more extensively studied in experimental models with obese subjects, and was shown to be a powerful GH releaser in obesity, and to release GH independently of the hypothalamic factors (GHRH and somatostatin).13
SARMs stimulate androgen receptors specifically in muscle and bone cells, hence assisting with muscle and bone growth, while having little effect on the other cells in the body (unlike regular steroids). They have a special affinity for certain tissues like muscle and bone, but not for others, like the prostate, liver, and brain. This means more rapid muscle and bone growth without unwanted growth in other parts of your body.
Adults do not stop producing growth hormone as they get older; in fact, it's a myth that's spread by the HRT/TRT industry. However, as you get older, it's harder to activate the body’s release or pulse of growth hormone as frequently as you did when you were still growing; hence, the term “when I was younger...”. Who doesn't remember how great they felt at 18, versus 38!

Figure 4: Influence of GHRP-6 on the expression of different gene families. RT-PCR experiments demonstrate the GHRP-6-induced reduction of the expression of its own receptor (Cd36). Concurrently, the peptide significantly reduced proinflammatory and profibrogenic cytokines. It is likely that the attenuation of these fibrogenic growth factors accounted for a reduction of extracellular matrix proteins and mesenchymal cells cytoskeleton proteins. Unpaired -test (, , and ).
MuscleSport PCT Stack 1x MuscleSport PCT Revolution 1x MuscleSport Test Revolution Black The MuscleSport PCT Stack is the ultimate Post Cycle Therapy supplement combo. Perfect for anyone who has spent time using anabolics or SARMs and want to ensure that their natural testosterone production is at its peak and that any excess estrogen is taken care of.  
Both paracetamol and caffeine are regarded as being well tolerated when used at therapeutic doses and there is a low risk of serious expected or serious unexpected adverse events with these products when taken either alone or in combination. Clinical data demonstrate that paracetamol combined with caffeine significantly out performs paracetamol alone. Paracetamol/caffeine formulations are well established globally. Such formulations are marketed in over 90 countries and have been available unscheduled ranging from 14 years to 25 years. Cumulative post-marketing experience to date with the sponsor’s paracetamol/caffeine combination products is estimated to be in excess of 488 million patients and has revealed no adverse safety signals or reasons for concern with the use of this product in an open sale environment.
In April and November 1994 and May 1995, the NDPSC decided to amend the scheduling of hydrogen peroxide to include exemptions for hair preparations: 6 per cent or less in the Schedule 5 entry because of the packaging and low exposure potential and 12 per cent or less in the Schedule 6 entry to capture hair dye preparations containing >6 per cent up to 12 per cent in Schedule 5. The NDPSC also decided that the hydrogen peroxide concentration would determine the appropriate warning statements.
Whether a peptide has some value or not will actually depend on the needs and goals of the bodybuilder. A number if peptides provide benefits that are naturally not found in other traditional medications. When we talk of muscle growth, you need to remember that taking proper bodybuilding peptides are the foundation of having a strong and better body.
Extreme hunger stimulation: It has been previously mentioned in this profile already that almost all GHRPs will stimulate hunger simply by virtue of the fact that they are Ghrelin mimetics (they mimic the action of the hormone Ghrelin in the body), but GHRP-6 has demonstrated both anecdotally as well as clinically to stimulate the largest hunger increases in comparison to all other GHRPs[2]. GHRP-6 tends to stimulate what can only be described as agonizing hunger, and is commonly misconceived as a hypoglycemic episode. The hunger resultant from GHRP-6 is, in fact, simply the peptide acting on Ghrelin receptors that signal hunger to various regions in the brain. No studies or any anecdotal evidence demonstrates hypoglycemic blood glucose readouts following GHRP-6 administration. Following a meal, the hunger should subside. Many users have also reported the intensity of the hunger diminishing several weeks into GHRP-6 cycles but not completely disappearing.
I was keen to try out CJC 1295 because my gym buddies had been using it for a while with fast and positive results. Though I was a bit nervous about injecting myself! To my surprise, it was easier than I expected. So I ordered online with Peptides Clinics and received a fast and efficient service. Everything came packaged in ice packs and with relevant info. Initially, I tried with the lowest dosage of CJC-1295 which was 10 mg for 10 weeks. It wasn’t look before I was seeing results. In fact, I noticed pretty quickly an increase in lean muscle, and couldn’t believe the amount of weight I lost! Brilliant! But, I have been advised to try out the CJC 1295 Ipamorelin combination, which I will do soon!
The availability of a pack size of 28 days' supply may result in the whole pack being used regardless of the pack being labelled with "14 day treatment". Consumers who initiate this treatment in a pharmacy setting may not see a medical practitioner for a month. If a consumer has not responded to treatment after 14 days, it is a flag for them to seek further medical assessment.
Technically, it is a “protein-peptide hormone” which means that it consists of 70 amino acids bonded together. Just like the peptides I’ve written about in the past, this means that it must be injected, because otherwise IGF-1 simply degrades in the gut, rendering it useless. Your own human growth hormone release promotes the synthesis of IGF-1 in your liver (and to smaller amounts, synthesis of IGF-1 by your muscles), your liver and muscles then synthesize IGF-1 and then, in the case of your liver, subsequently package the IGF-1 with binding proteins for transport into the blood. In a type of anabolic positive-feedback loop, IGF-1 then further increases growth hormone’s anabolic effects.
Exercise and sports have, in recent times gained the credit it is due. Not only are these sports a testament to the fortitude of the athletes, but they are also a science in themselves. Each sport has different exercise regimes and different dietary requirements. While some athletes face the same environment in each competition, there are those who have to face a different environment every time they compete. What remains constant however is the importance of growth hormone and the effect it has on the athlete’s body.
There is no “one right way”, to use Ipamorelin. For example, if you are using 500 to 1000 mcg doses daily, twice a day, your cycle might run for an 8 week period. If on the other hand, you are an athlete training for a competition, you might be on 3 injections per day, at 300-500 mcg, and will stay on for a 12 week period. For new users, you might find a 300 mcg injection is too high, and you will cut back to 200 mcg until your body gets used to it, for an 8-week cycle.

Studies have shown that individuals fighting infection have a lower amount of circulating T α 1 and suppressed helper T cell numbers compared to healthy individuals. This is problematic, as optimal immune function is vital to recovery from infection. Supplementation with T α 1 has the potential for great therapeutic benefit for patients suffering from infection or autoimmune disease.


Everybody has unique goals and these are best adjusted by your dosages. Research in The Journal Of Clinical Endocrinology & Metabolism found 100mcg will saturate all your receptors, but taking 200mcg will cough up an additional 50% of effectiveness, where as 300mcg delivers just a 25% of an additional boost. So the law of diminishing returns is firmly in place with this peptide. What’s more, higher doses were found in a study in The Journal Of Clinical Endocrinology & Metabolism to increase people’s stress hormone, cortisol in doses over a 100mcg so if you do decide to delve into this supplement, stick to the lower doses.
×